Abstract: AIM: To evaluate the effect and safety of fixed-dose glipizide/metformintablets on type 2 diabetes. METHODS: This was a double blind randomized 12-week clinical observation on multiple centers comparing the blood glucose lowering effect and safety between fixed-dose glipizide/metformin tablets and glipizide co-administered with metformin.RESULTS: The cohort consisted of 116 patients who received glipizide/metformin tablets and 118 taking glipizide and 118 taking metformin. The levels of glycosylated hemoglobin (HbA1c)were (5.5±1.3)%,(6.0±1.4)% and (6.1±1.5)%,the levels of fasting blood glucose (FBG) were (7.3±1.8),(7.9±2.3) and (8.2±2.4)mmol/L and the levels of 2 hours postprandial blood glucose (PBG 2 h) were (11.0±4.0),(12.2±4.2) and (12.5±4.5)mmol/L, in glipizide/metformin group, metformin group, glipizide group, after 12-week therapy. The level of 2 hours postprandial insulin was increased,but the fasting insulin level was significantly changed. The levels of TG were decreased in glipizide/metformin and metformin groups,and that in the glipizide group was increased . There were no statistical difference of the rates of side effect in three groups.CONCLUSION: Fixed-dose glipizide/metformin is a convenient, effective and safe blood glucose lowering drug for diabetic patients.

Key words: Type 2 diabetes, Metformin, Glipizde